奎硫平与奋乃静治疗精神分裂症疗效及依从性比较

目的:评价奎硫平治疗精神分裂症的疗效及依从性。方法:120例精神分裂症患者随机分为两组,分别给予奎硫平与奋乃静,治疗50周。以阳性症状与阴性症状量表(PANSS)评定疗效、以副反应量表(TESS)及血清催乳素评价不良反应。结果:治疗后8周奎硫平组PANSS总分减分率45.9%,有效率93.3%;奋乃静组分别为43.9%及90%;两组疗效与治疗前比较均差异具有显著性。治疗50周后,组间疗效比较,差异具有非常显著性。奎硫平组不良反应显著较少。结论:奎硫平是治疗精神分裂症有效且不良反应少的药物,但价格较高,可能影响患者的服药依从性。

Objective： to assess the compliance and effectiveness of quetiapine in treatment of schizophrenia. Methods ： 120 schizophrenia patients were randomly allocated to two groups, treated with quetiapine or perphenazine for 50 weeks respectively. Before and at the end of 8 ,50 weeks of treatment, the Positive and Negative Syndrome Scale （SPANSS） was used to assess the efficacy and Treatmnet Emergent Symtom Scale （TESS） and the level of serum prolactin （PRL） to assess the adverse effects. Re- suits：After 8 weeks, the decreasing rate of PANSS total scores is 45.9% and the efficacy rate is 93.3% in the quetiapine groups, while in the perphenazine groups are 43.9% and 90%. Signifficant improvement was observed respectively in the two groups. After 50 weeks, very signifficant difference was between the two groups and the side effects of quetiapine were less than that of perphenazine. Conclusion： Quetiapine is an effectine drug in the treatment of schizophrenia and its side effects are less. But the price of quetiapine probably effects its compliance.